Your AI-Trained Oncology Knowledge Connection!
Patients with node-positive breast cancer did not have a significant improvement in disease-free survival with the addition of internal mammary node irradiation to regional nodal irradiation; however, patients with medically or centrally located tumors could benefit.
Patients with relapsed/refractory B-cell non-Hodgkin lymphoma who experienced grade 3 or higher immune effector cell–associated neurotoxicity syndrome who were treated with early intrathecal therapy experienced improved survival.
Real-world practice patterns with bevacizumab for patients with ovarian cancer differed greatly from published clinical trial data.
In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.
Stereotactic body radiotherapy plus pembrolizumab and trametinib could potentially become a novel treatment strategy for patients with locally recurrent pancreatic cancer following surgery.
Patients with treatment-naïve chronic lymphocytic leukemia with the presence of deletion 17p who received treatment with ibrutinib in the first line were more likely to have poor survival and to discontinue treatment due to progression vs those without.
The primary end point of progression-free survival was not met in the phase 3 SKYSCRAPER-1 trial assessing tiragolumab plus atezolizumab for patients with PD-L1–high locally advanced or metastatic non–small cell lung cancer.
In this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.
Uday R. Popat, MD, spoke about the decision to use post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease.
Alina Markova, MD, highlights important findings from a study assessing topical ruxolitinib INCB018424 phosphate 1.5% cream as a treatment for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Investigators believe that molecular classification could be a predictor of survival in patients with recurrent endometrial cancer.
Patients with advanced human papillomavirus 16–positive cervical cancer appear to benefit from treatment with VB10.16 and atezolizumab.
In an interview with ONCOLOGY®, Megan May, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of dostarlimab as therapy for adult patients with recurrent or advanced solid tumors with deficient mismatch repair.
Tanios Bekaii-Saab, MD, sits with Kristen Ciombor, MD, MSCI, and John Strickler, MD, to examine the COLOMATE platform for patients with colorectal cancer.
Matthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.
Investigators identified that in pivotal clinical trials supporting FDA approvals of CAR T-cell therapies for patients with hematologic cancer, Black patients were significantly underrepresented.
Despite having a good rate of treatment adherence, patients who are diagnosed with high-risk stage III colorectal cancer at a younger age may have higher rates of relapse.
The phase 1/2 SPARTACUS trial assessed the use of stereotactic hypofractionated radiation therapy in patients with uterine cancer; the treatment appeared to be well tolerated.
At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about the role of pathology in renal cell carcinoma.
By reading CT scans, machine learning could aid investigators in improving treatment decision making.
Five-year follow-up findings highlighted a durable benefit among patients with advanced renal cell carcinoma following treatment with nivolumab plus ipilimumab compared with sunitinib.
Christine Chung, DO, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® about implications of blood-based molecular markers in pancreatic adenocarcinoma.
Minimal increases in genetic testing and counseling were observed when using a traceback program to contact patients with ovarian cancer and surrogates via phone, and was not time sensitive.
Nicolas Girard, MD, speaks with CancerNetwork® about the updated safety findings of nivolumab and chemotherapy in resectable non–small cell lung cancer.
Pembrolizumab has been approved by the European Commission in 5 indications of solid tumors that are microsatellite instability–high or deficient mismatch repair.
David M. O’Malley, MD, spoke about unmet needs of patients with advanced microsatellite instability–¬high or mismatch repair deficient endometrial carcinoma and the clinical benefit pembrolizumab provides.
Although treatment with polatuzumab vedotin (Polivy) after anti-CD19 CAR T-cell therapy was safe and effective for patients with relapsed/refractory large B-cell lymphoma, it had a short duration of response.
Minimal residual disease status 3 months and 6 months following autologous stem-cell transplant could be predictive of progression-free survival and overall survival outcomes in multiple myeloma.
Patients with metastatic castration-resistant prostate and DNA repair gene defects cancer treated with niraparib were found to experience significant anti-tumor activity.
Nina Shah, MD, spoke about her key takeaways from a sub-analysis of the phase 2 KarMMa trial assessing correlates of complete response among those treated with idecabtagene vicleucel in relapsed/refractory multiple myeloma.
